Showing results (301-310 of 369) with videos related to

Sort By:
Pageof 37
Circulation|April 9, 2021
Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HFPardeep S Jhund, Piotr Ponikowski, Kieran F Docherty, et al.
Circulation|November 19, 2019
Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF TrialMikhail N Kosiborod, Pardeep S Jhund, Kieran F Docherty, et al.
European Journal of Heart Failure|May 3, 2024
Dapagliflozin and quality of life measured using the EuroQol 5-dimension questionnaire in patients with heart failure with reduced and mildly reduced/preserved ejection fractionMingming Yang, Toru Kondo, Atefeh Talebi, et al.
Circulation. Heart Failure|October 27, 2023
Efficacy of Dapagliflozin According to Heart Rate: A Patient-Level Pooled Analysis of DAPA-HF and DELIVERToru Kondo, Jawad H Butt, James P Curtain, et al.
The New England Journal of Medicine|November 17, 2020
Sotagliflozin in Patients with Diabetes and Chronic Kidney DiseaseDeepak L Bhatt, Michael Szarek, Bertram Pitt, et al.
European Journal of Heart Failure|November 12, 2021
Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HFJawad H Butt, Kieran F Docherty, Pardeep S Jhund, et al.
JACC. Heart Failure|December 31, 2021
Efficacy of Dapagliflozin in Black Versus White Patients With Heart Failure and Reduced Ejection FractionKieran F Docherty, Modele O Ogunniyi, Inder S Anand, et al.
European Journal of Heart Failure|May 15, 2024
Effect of dapagliflozin in patients with diabetes and heart failure with mildly reduced or preserved ejection fraction according to background glucose-lowering therapy: A pre-specified analysis of the DELIVER trialMats Christian Højbjerg Lassen, John W Ostrominski, Silvio E Inzucchi, et al.
JACC. Heart Failure|June 9, 2023
Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Polypharmacy StatusAlexander Peikert, Parag Goyal, Muthiah Vaduganathan, et al.
Diabetes Care|December 23, 2020
Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HFSilvio E Inzucchi, Kieran F Docherty, Lars Køber, et al.
Pageof 37